12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Exclusion Criteria

• •Have any disease other than MS that could better explain his/her signs and symptoms
• •Receive any other injectable medications on a regular basis during the week prior to the screening period or throughout the duration of the study. The administration of a single injection for treatment or prophylaxis of a condition unrelated to the patient's MS or the patient's RNF therapy (e.g., influenza or pneumococcus vaccination) will be acceptable
• •Receive any MS therapy other than Rebif / RNF (e.g., other disease-modifying drug \[DMD\]s: immunomodulatory , immunosuppressive agents or combination therapy) within 12 months prior to study enrolment or at any time during the study
• •Receive oral or systemic corticosteroids or adrenocorticotrophic hormone (ACTH) within 30 days prior to SD1
• •Have inadequate liver function, defined by a alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or alkaline phosphatase \> 2 x ULN, or total bilirubin \> 2 x ULN if associated with any elevation of ALT or alkaline phosphatase
• •Have inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal
• •Have moderate to severe renal impairment
• •History of any chronic pain syndrome
• •Any visual or physical impairment that precludes the subject self-injecting the treatment using the RebiSmartä